Esperion Therapeutics, Inc. (ESPR)
NASDAQ: ESPR · Real-Time Price · USD
3.170
+0.020 (0.63%)
At close: Jun 26, 2026, 4:00 PM EDT
3.160
-0.010 (-0.32%)
After-hours: Jun 26, 2026, 7:17 PM EDT
Esperion Therapeutics Stock Forecast
Stock Price Forecast
The 6 analysts with 12-month price forecasts for Esperion Therapeutics stock have an average target of 2.92, with a low estimate of 1.78 and a high estimate of 3.28. The average target predicts a decrease of -7.89% from the current stock price of 3.17.
Analyst Consensus: Hold
* Price targets were last updated on May 4, 2026.
Analyst Ratings
The average analyst rating for Esperion Therapeutics stock from 6 stock analysts is "Hold". This means that analysts believe this stock is likely to perform similarly to the overall market.
Recommendation Trends
| Rating | Dec '25 | Jan '26 | Feb '26 | Mar '26 | Apr '26 | May '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 3 | 3 | 2 | 3 | 0 |
| Buy | 3 | 3 | 3 | 3 | 3 | 0 |
| Hold | 1 | 1 | 1 | 1 | 1 | 6 |
| Sell | 1 | 1 | 1 | 1 | 1 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 8 | 8 | 8 | 7 | 8 | 6 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Needham | Needham | Hold Maintains n/a | Hold | Maintains | n/a | n/a | May 12, 2026 |
| Jefferies | Jefferies | Hold Downgrades $3.28 | Hold | Downgrades | $3.28 | +3.47% | May 4, 2026 |
| H.C. Wainwright | H.C. Wainwright | Hold Downgrades $3.16 | Hold | Downgrades | $3.16 | -0.32% | May 4, 2026 |
| Piper Sandler | Piper Sandler | Hold Downgrades $9 → $3.16 | Hold | Downgrades | $9 → $3.16 | -0.32% | May 1, 2026 |
| Cantor Fitzgerald | Cantor Fitzgerald | Hold Downgrades $3.16 | Hold | Downgrades | $3.16 | -0.32% | May 1, 2026 |
Financial Forecast
Revenue This Year
337.60M
from 403.14M
Decreased by -16.26%
Revenue Next Year
456.69M
from 337.60M
Increased by 35.28%
EPS This Year
-0.21
from -0.11
EPS Next Year
0.29
from -0.21
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | 337.6M | 545.2M | |
| Avg | 337.6M | 456.7M | |
| Low | 337.6M | 297.9M |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | -16.3% | 61.5% | |
| Avg | -16.3% | 35.3% | |
| Low | -16.3% | -11.7% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | - | - | |
| Avg | -0.21 | 0.29 | |
| Low | - | - |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | - | - | |
| Avg | - | - | |
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.